We hereby submit the Outcome of Board Meeting held on 12.02.2026. Kindly take the same on your records.
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved unaudited standalone and consolidated financial results for Q3 FY26 (quarter ended Dec 31, 2025) and 9M FY26, with statutory auditors issuing an unqualified review report. On a consolidated basis, Q3 revenue from operations rose to Rs 5,199.64 lakhs from Rs 4,597.10 lakhs in Q3 FY25, a growth of about 13% year-on-year. Net profit after tax jumped to Rs 363.89 lakhs versus Rs 225.07 lakhs, up roughly 62% YoY. For nine months, revenue grew modestly to Rs 13,678.44 lakhs (Rs 13,137.17 lakhs prior), while PAT more than doubled to Rs 1,130.21 lakhs (Rs 519.87 lakhs prior). The Electronics segment drove growth with Q3 revenue of Rs 2,331.75 lakhs (up about 34% YoY), while Pharmaceuticals stayed largely flat at Rs 2,867.89 lakhs. The company booked an exceptional item of Rs 81.99 lakhs (net of tax) in Q3 related to one-time impact of India's new Labour Codes. Other income includes a Rs 400.70 lakhs reversal of past sales tax and customs duty provisions.
Profit growth is supported by operational improvement in Electronics and one-time non-operating gains (labour code provision, tax obligation reversal), so underlying earnings quality is partly flattered by these items. Modest top-line growth keeps the picture mixed, but the sharp PAT jump and unqualified audit opinion are positive signals for shareholders in the near term.